Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

Abstract

The study revealed heterogeneous mechanisms of resistance to osimertinib in advanced NSCLC patients and their association with clinical outcomes. Patients who maintained T790M mutation or with EGFR-dependent resistance mechanism had longer clinical outcome benefits.